By Zacks Equity Research | Zacks – 27 minutes ago
Alkermes plc (ALKS) recently announced positive results from a phase I study on its new antipsychotic candidate, ALKS 3831. ALKS 3831 is a combination of ALKS 33, and Eli Lilly and Company’s (LLY) Zyprexa (olanzapine).
Alkermes is developing ALKS 3831 for the treatment of schizophrenia and is designed to reduce the antipsychotic-related metabolic side effect of weight gain. Alkermes enrolled 106 healthy volunteers for the study.
Results from the study showed that weight gain in patients who were administered ALKS 3831 was significantly lower (an average of 2.5 kg) than in patients who took Zyprexa (an average of 3.4 kg). Alkermes also reported that ALKS 3831 was well tolerated in the study and the safety and tolerability results were almost similar to that of Zyprexa alone.
The company stated in its press release that weight gain is a common side effect in atypical antipsychotic medications and Zyprexa has the highest number of incidences and greatest amount of weight gain in this class of drugs.
Alkermes expects to initiate a phase II study on ALKS 3831 in mid-calendar 2013 after meeting the US Food and Drug Administration (:FDA) on the basis of the positive results from the phase I study.
We remind investors that the schizophrenia market is highly competitive with the presence of players like Eli Lilly and Novartis AG (NVS).
We currently have a Neutral recommendation on Alkermes. The stock carries a Zacks #3 Rank (Hold). Meanwhile, other pharma stocks such as Targacept, Inc. (TRGT) and Repligen Corporation (RGEN) carry a Zacks #1 Rank (Strong Buy).
Recent RGEN News
- Repligen Opens Training & Innovation Center to Elevate Customer Experience • GlobeNewswire Inc. • 09/24/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 08:21:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 03:35:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/10/2024 08:03:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 12:41:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 11:25:58 PM
- Repligen Corporation to Present at Wells Fargo Healthcare Conference • GlobeNewswire Inc. • 08/23/2024 11:30:00 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 08/19/2024 11:29:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 01:56:01 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/02/2024 07:26:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 12:47:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:04:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:11:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:07:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/30/2024 09:04:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 11:46:52 AM
- Repligen Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Repligen Announces Agreement to Acquire Chromatography Innovator Tantti • GlobeNewswire Inc. • 07/29/2024 08:00:00 PM
- Repligen to Report Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 07/16/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 08:05:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 10:07:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:42:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:41:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:33:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:15:56 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM